Safety and Efficacy Study of NGGT002 in cPKU Adult Subjects — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety and Efficacy Study of NGGT002 in cPKU Adult Subjects — Stella

Recruiting

Back to Phenylketonurias trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

China

First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui

Xinhua Hospital Affifiated to Shanghai Jiao Tong University School of Medicine, Shanghai

Key details

Phase

Early testing / Safety & dosing

Sponsor

NGGT (Suzhou) Biotechnology Co., Ltd.

Enrollment target

~18 participants

Started

July 2024

Primary completion

July 2026

Age range

18 Years – 55 Years

Last updated November 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov